logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10220051 B1

PDFFull Text
Date of Patent:
Mar. 05, 2019

Filed:

Nov. 13, 2014

Combination of dna repair inhibition with bendamustine or gemcitabine in the treatment of cancer

Applicant:

Institute for Cancer Research, Philadelphia, PA (US);

Inventors:

Alfonso Bellacosa, Philadelphia, PA (US);

Timothy Yen, Haverford, PA (US);

Neil Beeharry, Philadelphia, PA (US);

Mitchell Smith, Elkins Park, PA (US);

Rossella Tricarico, Philadelphia, PA (US);

Vikram Bhattacharjee, Philadelphia, PA (US);

Pietro Mancuso, Philadelphia, PA (US);

Assignee:

Institute For Cancer Research;

Attorney:

Stradley Ronon Stevens & Young, LLP

Primary Examiner:

James D Anderson

Int. Cl.
CPC ...
A61K 31/7068 (2006.01); A61K 31/4184 (2006.01); A61K 31/122 (2006.01); A61K 31/546 (2006.01); A61K 31/277 (2006.01); A61K 31/7088 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
A61K 31/7068 (2013.01); A61K 31/122 (2013.01); A61K 31/277 (2013.01); A61K 31/4184 (2013.01); A61K 31/546 (2013.01); A61K 31/7088 (2013.01); C12N 15/1137 (2013.01); C12N 2310/14 (2013.01); C12N 2320/31 (2013.01); C12Y 302/02029 (2013.01);
Abstract

The invention provides methods for enhancing the cytotoxicity of DNA damage in cancer cells that express thymine DNA glycosylase, and treating tumors accordingly. The methods comprise inhibiting the expression or biologic activity of thymine DNA glycosylase, and inducing DNA damage in the cancer cells. DNA damage may be induced by administration of bendamustine or gemcitabine to the cancer cells.

Find Patent Forward Citations

Bellacosa, Alfonso. (2019). Combination of dna repair inhibition with bendamustine or gemcitabine in the treatment of cancer (U.S. Patent No. 10220051). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10220051

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…